NCT04873440

An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma

Status unknown Phase 1, PHASE2 Last updated 5 May 2021

What this trial tests

Phase 1, PHASE2 trial testing Manganese Chloride in Solid Tumor in 10 participants. Status unknown.

Timeline

6 May 2021

Primary endpoint
31 May 2022

31 May 2023

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	6 May 2021
Primary completion	31 May 2022
Estimated completion	31 May 2023
Sites	1 location across China

Drugs / interventions tested

• Manganese Chloride (MANGANESE CHLORIDE) — full drug profile →
• Radiotherapy — full drug profile →
• Chemo-immunotherapy

Conditions studied

• Solid Tumor — all drugs for Solid Tumor →
• Lymphoma — all drugs for Lymphoma →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 18 to 80, any sex, with Solid Tumor or Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Radiotherapy is a regular care for metastatic solid tumors or lymphoma, and it can induce immunogenic death of tumor cells and a stronger immune response. Sometimes, tumor regression would be observed at sites distant to an irradiated field because of the radiotherapy-induced anticancer immune responses, so-called abscopal response. Manganese has been confirmed to activate innate immune and function as anticancer immunoadjuvant in pre-clinical studies. This study is designed to assess the abscopal response and safety of combined therapy of manganese and radiotherapy in patients with metastatic solid tumors or lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeting cytokine and chemokine signaling pathways for cancer therapy.
   Yi M, Li T, Niu M, Zhang H, et al · · 2024 · cited 264× · PMID 39034318 · DOI 10.1038/s41392-024-01868-3
2. Type I interferon-mediated tumor immunity and its role in immunotherapy.
   Yu R, Zhu B, Chen D. · · 2022 · cited 229× · PMID 35292881 · DOI 10.1007/s00018-022-04219-z
3. Exploiting innate immunity for cancer immunotherapy.
   Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
4. The abscopal effect in patients with cancer receiving immunotherapy.
   Nelson BE, Adashek JJ, Lin SH, Subbiah V. · · 2023 · cited 46× · PMID 36893753 · DOI 10.1016/j.medj.2023.02.003
5. Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes?
   Link B, Torres Crigna A, Hölzel M, Giordano FA, et al · · 2021 · cited 20× · PMID 34768644 · DOI 10.3390/jcm10215124
6. At the Crossroads of the cGAS-cGAMP-STING Pathway and the DNA Damage Response: Implications for Cancer Progression and Treatment.
   Korneenko TV, Pestov NB, Nevzorov IA, Daks AA, et al · · 2023 · cited 11× · PMID 38139802 · DOI 10.3390/ph16121675
7. Metallic nanomedicine in cancer immunotherapy.
   Li S, Wang X, Han H, Xiang S, et al · · 2025 · cited 2× · PMID 41049749 · DOI 10.1016/j.apsb.2025.07.017
8. Targeting immune checkpoint therapy: The role of manganese in tumor immunotherapy.
   Lyu X, Li B, Lin Z. · · 2026 · PMID 41732211 · DOI 10.1016/j.cpt.2025.10.001